SCHEMBL14459611

SCHEMBL14459611

Cc1cc(NC(=O)Oc2ccccc2)cc(C(=O)NC(C)C)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.54
▸ ALDH1A1 P00352 7/20 0.51
▸ GAA P10253 3/20 0.51
▸ MEN1 O00255 3/20 0.51
▸ KMT2A Q03164 3/20 0.51
▸ LMNA P02545 1/20 0.51
▸ TP53 P04637 1/20 0.51
▸ MAPT P10636 5/20 0.49
▸ FAAH O00519 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ KDM4E B2RXH2 2/20 0.46
▸ THRB P10828 2/20 0.46
▸ GFER P55789 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ HTT P42858 2/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ RAD51 Q06609 1/20 0.45
▸ POLB P06746 1/20 0.44
▸ HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14459621 0.87 CYP1A2 (0.57) CYP1A2ALDH1A1GAAMEN1KMT2A
SCHEMBL3984703 0.83 ALDH1A1 (0.63) CYP1A2ALDH1A1GAAMEN1KMT2A
SCHEMBL11668327 0.83 ALDH1A1 (0.63) CYP1A2ALDH1A1GAAMEN1KMT2A
SCHEMBL2480480 0.83 NPSR1 (0.54) CYP1A2ALDH1A1GAAMEN1KMT2A
SCHEMBL29739279 0.77 ALDH1A1 (0.55) CYP1A2ALDH1A1GAAMEN1KMT2A
SCHEMBL29739439 0.77 POLB (0.56) CYP1A2ALDH1A1GAAMEN1KMT2A
Phenyl M-Tolylcarbamate SCHEMBL29739712 0.75 ALDH1A1 (0.78) CYP1A2ALDH1A1GAAMEN1KMT2A
Phenyl M-Tolylcarbamate SCHEMBL259420 0.75 ALDH1A1 (0.78) CYP1A2ALDH1A1GAAMEN1KMT2A
SCHEMBL2813628 0.74 CYP1A2 (0.65) CYP1A2ALDH1A1GAAMEN1KMT2A
SCHEMBL2808736 0.74 CYP1A2 (0.65) CYP1A2ALDH1A1GAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541432-B2 Heterobicyclic carboxamides as inhibitors for kinases NOVARTIS AG (CH) 2013-09-24 — — US disclosed
US-8501756-B2 Heterobicyclic carboxamides as inhibitors for kinases NOVARTIS AG (CH) 2013-08-06 — — US disclosed
US-8492393-B2 Heterobicyclic carboxamides as inhibitors for kinases NOVARTIS AG (CH) 2013-07-23 — — US disclosed
US-8486954-B2 Heterobicyclic carboxamides as inhibitors for kinases NOVARTIS AG (CH) 2013-07-16 — — US disclosed
US-20130012529-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES NOVARTIS AG (CH) 2013-01-10 — — US disclosed
US-20130005753-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES NOVARTIS AG (CH) 2013-01-03 — — US disclosed
US-20130005750-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES NOVARTIS AG (CH) 2013-01-03 — — US disclosed
US-20130005751-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES NOVARTIS AG (CH) 2013-01-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005753-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES CDK2, PHKG1, PHKG2 CYP1A2 3953/4885ALDH1A1 3736/4885GAA 1780/4885
US-20130005751-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES CDK2, PHKG1, PHKG2 CYP1A2 3953/4885ALDH1A1 3736/4885GAA 1780/4885
US-20130005750-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES CDK2, PHKG1, PHKG2 CYP1A2 3953/4885ALDH1A1 3736/4885GAA 1780/4885
US-20130012529-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES CDK2, PHKG1, PHKG2 CYP1A2 3953/4885ALDH1A1 3736/4885GAA 1780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback